Vivani Medical (VANI) Stock Price, News & Analysis

Company Overview

Vivani Medical, Inc., a clinical stage company, develops various implants that treat chronic diseases with high unmet medical need. It engages in developing a portfolio of miniature drug implants to deliver minimally fluctuating drug profiles; and implantable visual prostheses devices to deliver useful artificial vision to blind individuals. The company is headquartered in Emeryville, California.

Key Stats

• Today's Range: $1.13 to $1.17
• 50-Day Range: $1.01 to $1.24
• 52-Week Range: $0.91 to $1.50
• Volume: 23,664 shs
• Average Volume: 97,112 shs
• Market Capitalization: $68.13 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $4.00
• Consensus Rating: Buy

Vivani Medical Stock Analysis - MarketRank™

Vivani Medical scored higher than 42% of companies evaluated by MarketBeat, and ranked 1930th out of 2,787 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

Vivani Medical has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

Vivani Medical has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Earnings Growth

Earnings for Vivani Medical are expected to remain at ($0.41) per share in the coming year.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vivani Medical is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vivani Medical is -2.70, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vivani Medical has a P/B Ratio of 3.87. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.15% of the float of Vivani Medical has been sold short.

Short Interest Ratio / Days to Cover

Vivani Medical has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vivani Medical has recently increased by 16.93%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vivani Medical does not currently pay a dividend.

Dividend Growth

Vivani Medical does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.15% of the float of Vivani Medical has been sold short.

Short Interest Ratio / Days to Cover

Vivani Medical has a short interest ratio ("days to cover") of 3.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vivani Medical has recently increased by 16.93%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 0.0 / 5
• News Sentiment: N/A

Search Interest

Only 1 people have searched for VANI on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 3.3 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Vivani Medical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $120,526.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

46.40% of the stock of Vivani Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 6.78% of the stock of Vivani Medical is held by institutions.

VANI Stock Analysis - Frequently Asked Questions

How have VANI shares performed this year?

Vivani Medical's stock was trading at $1.16 on January 1st, 2025. Since then, VANI shares have increased by 0.0% and is now trading at $1.16.
View the best growth stocks for 2025 here.

How were Vivani Medical's earnings last quarter?

Vivani Medical, Inc. (NASDAQ:VANI) issued its quarterly earnings results on Tuesday, May, 13th. The company reported ($0.11) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.01.

Who are Vivani Medical's major shareholders?

Vivani Medical's top institutional shareholders include Connective Capital Management LLC (0.27%) and Wealthedge Investment Advisors LLC (0.21%). Insiders that own company stock include Gregg Williams, Joachim Eberhard Bolck, Aaron Mendelsohn, Donald Dwyer and Brigid Makes.
View institutional ownership trends.

How do I buy shares of Vivani Medical?

Shares of VANI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vivani Medical own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vivani Medical investors own include Second Sight Medical Products (EYES), Enterprise Products Partners (EPD), Nextera Energy Partners (NEP), Altimmune (ALT), Caribou Biosciences (CRBU) and Enbridge (ENB).

Company Calendar

• Last Earnings: 5/13/2025
• Today: 6/20/2025
• Next Earnings (Estimated): 8/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - DRUGS
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:VANI
• CIK: 1266806
• Web: www.vivani.com
• Phone: (818) 833-5000
• Fax: 818-833-5067
• Employees: 20
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $4.00
• High Stock Price Target: $4.00
• Low Stock Price Target: $4.00
• Potential Upside/Downside: +244.8%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.43)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$23.49 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -133.07%
• Return on Assets: -56.50%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.40
• Quick Ratio: 2.40

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.30 per share
• Price / Book: 3.87

Miscellaneous

• Outstanding Shares: 59,244,000
• Free Float: 31,755,000
• Market Cap: $68.72 million
• Optionable: Optionable
• Beta: 2.93